grant

A novel approach for treating B-cell lymphoma by inhibition of the E3 ligase E6AP [ 2012 - 2014 ]

Also known as: Treatment of B-cell lymphoma by targetting protein degradation

Funded by National Health and Medical Research Council
Managed by The University of Melbourne
Managed by University of Melbourne
Provided by   National Health and Medical Research Council

Research Grant

[Cite as https://purl.org/au-research/grants/nhmrc/1026988]

Researchers: Prof Ygal Haupt (Principal investigator) ,  Prof Grant Mcarthur

Brief description B-cell lymphoma is the most common type blood cancer diagnosed in Australia, and Australia's fifth most common cancer. Despite remarkable advances in diagnosis and treatment, lymphoma continues to rank as a leading cause of cancer-related mortality. Our pilot studies reveal a novel approach to treatment of B-cell lymphoma by inhibiting an enzyme that destroys our natural mechanism of defense against cancer. In this study we will test the efficacy of this novel treatment.

Funding Amount $AUD 624,846.33

Funding Scheme Project Grants

Notes Standard Project Grant

Click to explore relationships graph
Help

Related Organisations

Related People

Subjects
Medical and Health Sciences | Molecular Targets | Oncology and Carcinogenesis | anticancer drug | cancer chemotherapeutic agents | haematological malignancy | human malignant B-cell lymphoma | lymphoma | molecular oncology | p53 | protein degradation | tumour suppressor gene |
Identifiers
Viewed: [[ro.stat.viewed]]
Saved to MyRDA Save to MyRDA